{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T10:55:39Z","timestamp":1791111339262,"version":"4.1.0"},"reference-count":14,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2022,2,1]]},"DOI":"10.1001\/jamadermatol.2021.4805","type":"journal-article","created":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T18:03:51Z","timestamp":1638381831000},"page":"184","source":"Crossref","is-referenced-by-count":35,"title":["Drug Survival of Biologics in Patients With Hidradenitis Suppurativa"],"prefix":"10.1001","volume":"158","author":[{"given":"Hans Christian","family":"Ring","sequence":"first","affiliation":[{"name":"Department of Dermato-Venereology & Wound Healing Centre, Bispebjerg Hospital, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia-Tatjana","family":"Maul","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Z\u00fcrich, Z\u00fcrich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqiu","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Dermato-Venereology & Wound Healing Centre, Bispebjerg Hospital, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jashin J.","family":"Wu","sequence":"additional","affiliation":[{"name":"Dermatology Research and Education Foundation, Irvine, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob P.","family":"Thyssen","sequence":"additional","affiliation":[{"name":"Department of Dermato-Venereology & Wound Healing Centre, Bispebjerg Hospital, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon F.","family":"Thomsen","sequence":"additional","affiliation":[{"name":"Department of Dermato-Venereology & Wound Healing Centre, Bispebjerg Hospital, Copenhagen, Denmark"},{"name":"Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Egeberg","sequence":"additional","affiliation":[{"name":"Department of Dermato-Venereology & Wound Healing Centre, Bispebjerg Hospital, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"dbr210024r1","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMcp1014163","article-title":"Clinical practice: hidradenitis suppurativa.","volume":"366","author":"Jemec","year":"2012","journal-title":"N Engl J Med"},{"issue":"4","key":"dbr210024r2","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.jaad.2016.10.042","article-title":"Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: implications for treatment with anti-IL-17 agents.","volume":"76","author":"Matusiak","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"dbr210024r3","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1111\/j.1365-2133.2011.10254.x","article-title":"Elevated levels of tumour necrosis factor (TNF)-a, interleukin (IL)-1\u00df and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-a and IL-1\u00df.","volume":"164","author":"van der Zee","year":"2011","journal-title":"Br J Dermatol"},{"issue":"5","key":"dbr210024r4","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two phase 3 trials of adalimumab for hidradenitis suppurativa.","volume":"375","author":"Kimball","year":"2016","journal-title":"N Engl J Med"},{"issue":"12","key":"dbr210024r5","doi-asserted-by":"publisher","first-page":"846","DOI":"10.7326\/0003-4819-157-12-201212180-00004","article-title":"Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: a parallel randomized trial.","volume":"157","author":"Kimball","year":"2012","journal-title":"Ann Intern Med"},{"issue":"1","key":"dbr210024r6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/jdv.2019.33.issue-1","article-title":"Hidradenitis suppurativa\/acne inversa: a practical framework for treatment optimization\u2014systematic review and recommendations from the HS ALLIANCE working group.","volume":"33","author":"Zouboulis","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"dbr210024r7","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/bjd.v185.1","article-title":"Adalimumab and infliximab survival in patients with hidradenitis suppurativa: a daily practice cohort study.","volume":"185","author":"Prens","year":"2021","journal-title":"Br J Dermatol"},{"issue":"1","key":"dbr210024r8","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3109\/09546634.2013.879092","article-title":"Adherence to TNF-alpha inhibitors in patients with hidradenitis suppurativa.","volume":"26","author":"Thomsen","year":"2015","journal-title":"J Dermatolog Treat"},{"issue":"12","key":"dbr210024r9","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1001\/jamadermatol.2014.1165","article-title":"Association of metabolic syndrome and hidradenitis suppurativa.","volume":"150","author":"Miller","year":"2014","journal-title":"JAMA Dermatol"},{"issue":"2","key":"dbr210024r10","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/bjd.16102","article-title":"Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis.","volume":"178","author":"Egeberg","year":"2018","journal-title":"Br J Dermatol"},{"issue":"2","key":"dbr210024r11","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1007\/s11096-020-00978-6","article-title":"Comparison of drug survival between infliximab and adalimumab in inflammatory bowel disease.","volume":"42","author":"Gil-Candel","year":"2020","journal-title":"Int J Clin Pharm"},{"issue":"6","key":"dbr210024r12","doi-asserted-by":"publisher","first-page":"785","DOI":"10.3899\/jrheum.170477","article-title":"Comparative analysis and predictors of 10-year tumor necrosis factor inhibitors drug survival in patients with spondyloarthritis: First-year response predicts long term drug persistence.","volume":"45","author":"Flouri","year":"2018","journal-title":"J Rheumatol"},{"issue":"9","key":"dbr210024r13","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1001\/jamadermatol.2017.0904","article-title":"The follicular skin microbiome in patients with hidradenitis suppurativa and healthy controls.","volume":"153","author":"Ring","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"9","key":"dbr210024r14","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1111\/jdv.v33.9","article-title":"The microbiome of tunnels in hidradenitis suppurativa patients.","volume":"33","author":"Ring","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2786913\/jamadermatology_ring_2021_br_210024_1643827861.37874.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T16:07:55Z","timestamp":1645027675000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2786913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,1]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2021.4805","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2,1]]}}}